Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs First patient has been treated in Germany in Immatics ACTengine IMA202-101 trial German regulatory agency, Paul-Ehrlich-I

Immatics Announces European Clinical Expansion of its

Adoptive Cell Therapy Programs

Tuebingen, Germany and Houston, Texas,

August 18, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the

treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the

regulatory body for cell and gene therapies in Germany. In addition, Immatics has been granted regulatory approval by PEI to initiate another phase I clinical trial in Germany to evaluate safety, tolerability and initial signs of clinical efficacy

The clinical trials of the IMA200 series will investigate up to three novel cancer immunotherapies, which include IMA202 (NCT03441100)

and IMA203 (NCT03686124). IMA202 and IMA203 are designed to target unique peptides derived from either melanoma-associated antigen 1 ( MAGEA1 ) or preferentially expressed antigen in melanoma ( PRAME ), respectively. Both

are built on Immatics proprietary ACTengine approach in which the patient s own T cells are genetically engineered to express an exogenous T cell receptor (TCR) directed against

true cancer targets. By introducing this novel cancer specific TCR, the goal is to redirect and selectively activate the patient s T cells to fight the tumor. The studies will investigate the safety and tolerability of Immatics Adoptive

Cell Therapies (ACT) in patients with target-positive solid cancers and seek initial signals of anti-tumor activity. Moreover, persistence of the infused engineered T cells will be monitored in the patient s blood as T cell persistence is

considered a major pre-requisite to obtain an anti-tumor response. The aim is to develop innovative personalized immunotherapies, targeting a patient s tumor selectively and effectively.

The initial group of clinical trial sites in Germany includes the University Hospital Carl Gustav

Carus in Dresden, the University Hospital Bonn and the University Hospital of W rzburg. Previous patients in the IMA200 series were initially enrolled at The University of Texas MD Anderson Cancer Center in Houston,

Texas, and more recently at the Columbia University Irving Medical Center in New York and the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.

Cedrik Britten, MD, Chief Medical Officer of Immatics commented: As part of our strategy to increase the geographical foot-print for our clinical sites,

we are currently expanding them in the US and in Europe. We are delighted to have gained a new regulatory approval from PEI and to have treated the first patient in Germany. This expansion elevates our clinical organization to a global level and

adds operational flexibility that has become even more important in the light of the global COVID-19 pandemic. We look forward to continuing to collaborate with leading clinicians to advance our mission of

delivering the power of T cells to cancer patients on both sides of the Atlantic.

Dr. Martin Wermke, Coordinating Investigator and Head of the

Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany, commented: Having been involved since the early stages of this clinical research, I am

excited to witness the next phase of development of this fascinating pipeline of immunotherapies. I am confident that Immatics innovative T cell therapies hold the potential to alter the future therapeutic landscape of solid and hematologic

Additional information about the clinical studies is available at www.immatics.com/clinical-programs/ and

www.clinicaltrials.gov.

About Immatics Adoptive Cell Therapies

Adoptive Cell Therapy (ACT) is a therapeutic approach that uses natural or engineered T cells to fight cancer. Immatics has developed three innovative,

proprietary approaches to produce Adoptive Cell Therapies: ACTengine , off-the-shelf ACTallo and the multi-target pilot trial ACTolog .

Immatics clinical product class ACTengine is a personalized approach for patients with advanced

solid cancers. Patient s own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics cancer targets identified by its proprietary XPRESIDENT

target discovery platform.

About the ACTengine clinical trials (IMA201,

Patient receiving an investigational therapy based on Immatics ACTengine approach.

Immatics combines the discovery of true

targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation

for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their

fight against cancer.

Immatics pipeline consists of two distinct therapeutic modalities of Adoptive Cell Therapies and TCR Bispecifics.

Adoptive Cell Therapy programs are developed in collaboration through Immatics US with The University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas

(CPRIT). The ACT T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth.

Forward-Looking Statements:

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or

Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can

identify forward-looking statements by terminology such as may , should , expect , intend , will , estimate , anticipate , believe , predict ,

potential or continue , or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to

differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently

uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to,

various factors beyond management s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded

as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on

forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

For more information, please contact:

You have received this information due to your interest in Immatics (Immatics N.V. / Immatics Biotechnologies GmbH / Immatics

US, Inc.). We hope you find this information useful to update you on the developments at Immatics.

Immatics would like to continue to send you

information by Email. If you would prefer not to receive these Emails, please unsubscribe here.